6533b859fe1ef96bd12b6eab

RESEARCH PRODUCT

Zinc oxide nanorod based immunosensing platform for the determination of human leukemic cells.

Raimonds PoplausksEkaterina SlobozhaninaYuliya HarmazaDonats ErtsLina Mikoliu̅naitėRoman ViterRoman ViterAlmira RamanavicieneArunas RamanaviciusDaniels JevdokimovsAlexander Tamashevski

subject

Monoclonal antibodymedicine.drug_class02 engineering and technologyCell SeparationMonoclonal antibody01 natural sciencesCD19Analytical ChemistryFlow cytometrychemistry.chemical_compoundHuman lymphocytesmedicineHumansFlow cytometryZnO-nanorodsFluorescein isothiocyanatePhotoluminescenceCells CulturedImmunoassayB-LymphocytesLeukemiaNanotubesCluster of differentiationmedicine.diagnostic_testbiology010401 analytical chemistryhemic and immune systemsВ-lymphoblast cells021001 nanoscience & nanotechnologyFlow CytometryMolecular biologyhumanities0104 chemical scienceschemistryCell cultureCancer cell:NATURAL SCIENCES [Research Subject Categories]biology.proteinAntibodyZinc Oxide0210 nano-technologyhuman activitiesBiomarkers

description

Zinc oxide (ZnO) based nanostructures owing unique physical properties – high photoluminescence, bio- compatibility and other characteristics, therefore, they attract attention as building blocks suitable for biosensor development. In this research as a target we have used human leukemic cell line IM9 (IM9). IM9 was derived from the patient with a multiple myeloma and expressed cluster of differentiation proteins СD19 on the surface of 85–95% here investigated cancer cells. As a control sample healthy human's peripheral blood mononuclear cells (PBMC) were used and the expression of CD19 protein was found only in 5–9% of these cells. Two types of antibodies labeled by fluorescein isothiocyanate (FITC) were used for the labeling of human leukemic cells: FITC-conjugated mouse antibodies against Human CD19 protein (anti-CD19-FITC*) and FITC-conjugated mouse antibodies against Human IgG1 protein (anti-IgG1-FITC*). In order to demonstrate the applicability of zinc oxide nanorods (ZnO-NRs) based platforms three types of ZnO-NRs-based structures were investigated: (i) ZnO-NRs modified by anti-CD19-FITC*; (ii) ZnO-NRs modified by IM9 cells, which were pre-incubated with anti-CD19- FITC*; (iii) ZnO-NRs modified by PBMC cells, which were pre-incubated with anti-CD19-FITC*. It was de- monstrated that IM9 cells after specific interaction with anti-CD19-FITC* bind to ZnO-NRs (ZnO-NRs/ IM9 +anti-CD19-FITC*) and photoluminescence based signal significantly increase in comparison with that observed in control samples, which contained PBMC cells incubated with anti-CD19-FITC*(ZnO-NRs/ PBMC+anti-CD19-FITC*). The photoluminescence results are in good correlation with the data obtained by flow cytometry. This study illustrate that ZnO-NRs exhibit a photoluminescence signal suitable for the determination of anti-CD19-FITC* labeled IM9 cell line at concentrations – from 10 till 500 cells adsorbed per 1 mm2 of ZnO- NRs platform.

10.1016/j.talanta.2019.03.064https://pubmed.ncbi.nlm.nih.gov/31036199